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Mid-term follow-up after heart valve replacement 
with CarboMedics bileaflet prostheses 
To the Editor: 
I read with interest he article by de Luca and associ- 
ates I concerning valve replacement with the CarboMedics 
bileaflet prosthesis, and I commend them for providing 
valuable information to help surgeons evaluate the re- 
cently approved CarboMedics valve (CarboMedics, Inc., 
Austin, Tex.). The authors have carefully adhered to the 
published guidelines for reporting valve-related complica- 
tions 2 in virtually all areas. The completeness of their 
follow-up and the detail of their presentation are admira- 
ble. 
One area of their report has results that appear to be 
misleading, namely, the presentation of linearized rates of 
valve-related complications reported for aortic, mitral, 
and double valve replacement. The presentation of accu- 
rate information is important, because on page 1163 of 
their report the authors state that their incidence of 
thromboembolic complications is low, at 0.5%/pt-yr, com- 
pared with other series. Analysis of the information 
provided in the Results section on page 1160 reveals that 
the linearized rates calculated for the individual events are 
probably erroneous. For example, the authors state on 
page 1160 that thromboembolic events were observed in 
seven patients. If the cumulative patient follow-up was 478 
patient-years, asstated on page 1159, then the linearized 
rate for thromboembolism would be 1.5%/pt-yr, not 0.5%/ 
pt-yr. 
A further difficulty arises when the authors present 
linearized rates segregated according to valve procedure. 
Although they do not provide us with a breakdown of the 
individual events by operative procedure, their report of 
the linearized rates of thromboembolism for aortic 
(0.35%/pt-yr), mitral (0.8%/pt-yr), and double valve re- 
placement (0.3%/pt-yr) cannot be correct. Linearized 
rates for valve-related complications separated according 
to valve operation must be divided by the patient-years of 
follow-up for only that valve operation group to accurately 
represent the linearized rate. The authors appear to have 
generated a "linearized rate" by dividing the percentage 
of patients free of an event actuarially by the follow-up 
interval of 31/2 years. 
Similar computational errors can be found in the pre- 
sentations of valve-related eath, anticoagulant-related 
hemorrhage, nonstructural valvular dysfunction, pros- 
thetic valve endocarditis, and incidence of reoperation. In
terms of sustaining the high quality of their report, I ask 
that de Luca and colleagues generate accurate linearized 
rates for the valve-related complications that they have 
noted for the combined and separate operative proce- 
dures. This information would be valuable for cardiac 
surgeons who are seeking to generate data 3 that allow 
comparison of the various available prostheses, with an 
aim toward finding the most appropriate prostheses for 
their patients. 
Cary W. Akins, MD 
Department of Cardiac Surgery 
Massachusetts General Hospital 
Boston, MA 02114 
REFERENCES 
1. de Luca D, Vitale N, Giannolo B, et al. Mid-term 
follow-up after heart valve replacement with Carbo- 
Medics bileaflet prostheses. J TnORAC CAm~IOVASC 
SURG 1993;106:1158-65. 
2. Edmunds LH, Clark RE, Cohn LH, et al. Guidelines 
for reporting morbidity and mortality after cardiac 
valvular operations. J TnOP, AC CAPd~IOVASC St:R6 1988; 
96:351-3. 
3. Akins CW. Mechanical cardiac valvular prostheses. 
Ann Thorac Surg 1991;52:161-72. 
12/8/65675 
Reply to the Editor: 
We appreciate the opportunity to respond to the com- 
ments of Dr. Akins regarding our article. ~ He gave us the 
benefit of his experience. 2 
With regard to linearized rates of valve-related compli- 
cations, data were analyzed by applying the Mantel- 
Haenszel test included in the program 1L of the BMDP 
statistical software package (BMDP Statistical Software, 
Inc., Los Angeles, Calif.). 3 This test takes into account he 
number of events for a given time divided by the number 
of patients followed up for the same time interval)' 4 In 
our study we assumed a 6-month interval. This type of 
calculation is presented in our article as the curve at the 
bottom of each graph. The combined and separate linear- 
ized rates presented in our report were obtained with this 
test, by summing up the patient-year incidences of each 
time interval divided by the total number of time intervals 
of follow-up)' 4 Moreover, linearized rates of each sub- 
group of patients were calculated including only the 
patients undergoing that operative procedure. For all 
these reasons, they would be better defined as linearized 
incidences than as linearized rates, and we apologize not to 
have mentioned this statistical aspect in our paper. 
On the other hand, linearized rates are generated by the 
number of events divided by the number of patient-years. 
As requested by Dr. Akins, we list the linearized rates of 
our population for the valve-related complications that we 
have noted for the combined and separate operative 
procedures (Table I). The rates were calculated according 
to this latter method. 
We are grateful to Dr. Akins for raising this statistical 
issue of our paper that would have been overlooked 
Table I. Linearized rates of valve-related 
complications 
Total MVR A VR D VR 
Event (%/pt-yr) (%/pt-yr) (%/pt-yr) (%/pt-yr) 
NSD 0.6 - -  0.5 2 
ARH 1 - -  1.5 2 
TE 1.5 2.9 1 - -  
Reoperation 0.6 1.7 - -  - -  
PVE 0.2 - -  0.5 - -  
VRD 1.5 1.2 1.5 2 
ARH, Anticoagulant-related h morrhage; AVR, aortic valve replacement; 
DVR, double (mitral and aortic) valve replacement; MVR, mitral valve 
replacement; NSD, nonstructural dysfunction; PVE, prosthetic valve endo- 
earditis; TE, thromboembolie events; VRD, valve-related eaths. 
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otherwise. A correct analysis of data on cardiac valvular 
prostheses allows a better understanding of the results of 
such procedures and enables surgeons to choose the 
appropriate prostheses for their patients. 
Nicola Vitale, MD 
Luigi de Luca, MD 
Istituto di Cardiochirurgia 
Universitiz d Bari 
Piazza GiuIio 11 
70124 Bari, Italy 
Maurizio Cotmfo, MD 
Istituto di Cardiochirurgia 
Seconda Universit~ di Napoli 
Ospedale V. Monaldi 
Via L. Banchi 3 
80100 Napoli, Italy 
REFERENCES 
1. de Luca l,, Vitale N, Giannolo B, et al. Mid-term 
follow-up after heart valve replacement with Carbo- 
Medics bileaflet prostheses. J THORAC CARDIOVASC 
SVRG 1993;106:1158-65. 
2. Akins CW. Mechanical cardiac valvular prostheses. 
Ann Thorac Surg 1991;52:161-72. 
3. BMDP Program 1L. BMDP statistical software man- 
ual. Vo! 2. Los Angeles: University of California Press, 
1990. 
4. Colton T. Statistics in medicine. Boston: Little Brown, 
1978. 
12/8/65676 
Tracheal sleeve pneumonectomy for bronchogenic 
carcinoma 
To the Editor: 
The January 1994 issue of this JOURNAL included our 
article, titled "Tracheal Sleeve Pneumonectomy forBron- 
chogenic Carcinoma" (J THORAC CARDIOVASC SURG 94; 
107:13-8). The work reported our experience with 28 
tracheal sleeve pneumonectomies (TSPs), 27 right TSPs 
and one left TSP. The very low operative mortality (only 
one death, which occurred on the thirtieth postoperative 
day as a result of myocardial infarction) and the absence 
of anastomotic complications (stenosis and dehiscence) 
seemed to impress the readers, as indicated by the many 
reprint reque.sts and letters with specific questions on 
technical details of tracheobronchial anastomosis, on an- 
esthesia modalities, and on preoperative and postopera- 
tive care. 
High mortality rates are commonly reported in the 
literature (8% to 29%). The progress of ventilation tech- 
niques and of suture-performing modalities have allowed 
acceptanc e of TSP. Nevertheless, TSP is still carried out 
only in centers highly qualified to perform thoracic sur- 
gery. 
From 1992 (when the period of observation ended) to 
date we have performed seven more right TSPs on 
patients with lung cancer involving the tracheobronchial 
angle. In this last group of patients we recorded two 
deaths caused by postoperative complications which, in 
our opinion, were due to inappropriate preoperative 
radiotherapy. In this letter we would like to stress the 
negative effects of high-dose radiotherapy in patients 
eligible for TSP. 
Like other authors, we adopted preoperative radiation 
treatment to reduce the tumor size, so as to facilitate the 
anastomotic procedure. We chose the low-dose protocol 
introduced by Paulson and associates, 1 reserving it for 
large neoplasms that might be expected to benefit most 
from combined radiotherapeutic and surgical treatment. 
No radiotherapy is planned in small tumors. 
In our series, of 35 patients subjected to TSP, 14 
received a preoperative radiotherapy protocol consisting 
of 10 treatments of 30 Gy each. One patient had preop- 
erative chemotherapy. Another patient had both radio- 
therapy and chemotherapy. Seventeen patients did not 
receive any preoperative treatment. Two patients had 
high-dose radiotherapy (60 Gy). Their clinical history and 
the reasons for the high-dose radiation treatment, which 
in our opinion caused the patients' deaths, are briefly 
described. 
The first patient, a 67-year-old man, was counselled to 
receive radiotherapy in 30 Gy doses. We were unaware 
that his son, who is a physician, decided to subject the 
patient to 60 Gy doses. Evaluation after radiotherapy 
showed a good result and the patient was therefore 
subjected to TSP. The postoperative course was normal 
until the ninth postoperative day, when clinical and roent- 
genographic signs of bronchial fistula developed. A bron- 
choscopic examination showed a hyperemic anastomosis 
covered with fibrin and without any sign of tissue healing: 
the endoscopic picture closely resembled that of the 
immediate postoperative p riod. A small bronchial fistula 
was found on the right edge of the suture. A tracheostomy 
was done and the patient was intubated with the same 
tube (Sybilla's tube) that we used to carry out the anas- 
tomosis, by inflating the balloon distal to the anastomosis. 
The pleural cavity was drained. The patient had a number 
of complications, and he died on postoperative day 22 of 
a fatal hemorrhage from a gastric ulcer. Repeated bron- 
choscopic studies during the course had all failed to show 
granulation tissue or other signs of healing on the anas- 
tomosis. 
The second patient was a 71-year-old man. Despite our 
prescription for preoperative radiation therapy in 30 Gy 
doses, his condition was judged inoperable by the radio- 
therapist who therefore subjected him to 60 Gy doses. 
This treatment yielded a remarkable reduction of the 
mass. Because we were not sure of the actual responsibil- 
ity of excessive preoperative radiation in determining 
bronchial dehiscence in the previous case, and considering 
the good general conditions of this patient, we decided to 
perform TSP. 
On the first postoperative day a conspicuous bronchor- 
rhea developed that necessitated repeated bronchial suc- 
tions. The patient died on the eighth postoperative day of 
pulmonary edema. A bronchoscopic examination had 
revealed a normal tracheobronchial anastomosis. 
Jensik and coworkers, 2 in an article published in 1982, 
had already stressed the fact that postoperative mortality 
